192 related articles for article (PubMed ID: 16624341)
1. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
2. Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization.
Bagley RG; Honma N; Weber W; Boutin P; Rouleau C; Shankara S; Kataoka S; Ishida I; Roberts BL; Teicher BA
Microvasc Res; 2008 Nov; 76(3):180-8. PubMed ID: 18761022
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer.
Dango S; Sienel W; Schreiber M; Stremmel C; Kirschbaum A; Pantel K; Passlick B
Lung Cancer; 2008 Jun; 60(3):426-33. PubMed ID: 18215438
[TBL] [Abstract][Full Text] [Related]
4. Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy.
Bagley RG; Weber W; Rouleau C; Teicher BA
Cancer Res; 2005 Nov; 65(21):9741-50. PubMed ID: 16266995
[TBL] [Abstract][Full Text] [Related]
5. Tumor angiogenesis of non-small cell lung cancer.
Shijubo N; Kojima H; Nagata M; Ohchi T; Suzuki A; Abe S; Sato N
Microsc Res Tech; 2003 Feb; 60(2):186-98. PubMed ID: 12539173
[TBL] [Abstract][Full Text] [Related]
6. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
Reinmuth N; Steins M; Kreuter M; Thomas M
Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of angiogenesis with the expression of VEGF and CD34 in human non-small cell lung cancer.
Inda AM; Andrini LB; García MN; García AL; Fernández Blanco A; Furnus CC; Galletti SM; Prat GD; Errecalde AL
J Exp Clin Cancer Res; 2007 Sep; 26(3):375-8. PubMed ID: 17987799
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
9. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer.
Koukourakis MI; Papazoglou D; Giatromanolaki A; Bougioukas G; Maltezos E; Sivridis E
Lung Cancer; 2004 Dec; 46(3):293-8. PubMed ID: 15541813
[TBL] [Abstract][Full Text] [Related]
10. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
[TBL] [Abstract][Full Text] [Related]
12. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
13. Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Hong TM; Chen YL; Wu YY; Yuan A; Chao YC; Chung YC; Wu MH; Yang SC; Pan SH; Shih JY; Chan WK; Yang PC
Clin Cancer Res; 2007 Aug; 13(16):4759-68. PubMed ID: 17699853
[TBL] [Abstract][Full Text] [Related]
14. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.
Olaso E; Vidal-Vanaclocha F
Methods Mol Med; 2003; 85():79-86. PubMed ID: 12710199
[No Abstract] [Full Text] [Related]
15. Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer.
Blackhall FH; Shepherd FA
Hematol Oncol Clin North Am; 2004 Oct; 18(5):1121-41, ix. PubMed ID: 15474338
[TBL] [Abstract][Full Text] [Related]
16. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer.
Donnem T; Al-Saad S; Al-Shibli K; Delghandi MP; Persson M; Nilsen MN; Busund LT; Bremnes RM
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6649-57. PubMed ID: 18006765
[TBL] [Abstract][Full Text] [Related]
17. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
[TBL] [Abstract][Full Text] [Related]
18. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
19. [The actual place of anti-angiogenesis in non-small cell lung cancer].
Mennecier B
Rev Mal Respir; 2007 Oct; 24(8 Pt 2):6S198-205. PubMed ID: 18235414
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
Lu C; Kamat AA; Lin YG; Merritt WM; Landen CN; Kim TJ; Spannuth W; Arumugam T; Han LY; Jennings NB; Logsdon C; Jaffe RB; Coleman RL; Sood AK
Clin Cancer Res; 2007 Jul; 13(14):4209-17. PubMed ID: 17634550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
